Gastrointestinal Diseases
Show Only Open Trials
1.
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
- Study Status: Open to Enrollment
- Sponsor: Janssen
- Disease Status and/or Stage: Moderate to Severe Crohn's Disease
2.
Evaluation of PROCHYMAL Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease
- Study Status: Open to Enrollment
- Sponsor: Osiris
- Disease Status and/or Stage: Moderate to Severe Crohn's Disease
- Protocol ID: Osiris 603
3.
CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring
- Study Status: Open to Enrollment
- Sponsor: Elan Pharmaceuticals
- Disease Status and/or Stage: Crohn's Disease Being Treated with TYSABRI
4.
Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy
- Study Status: Open to Enrollment
- Sponsor: Bristol-Myers Squibb
- Disease Status and/or Stage: Chronic Hepatitis C, Untreated or Previously Treated
- Protocol ID: BMS AI452021
5.
GS-US-321-0105: GS-6624 in the Treatment of Liver Fibrosis in Subjects With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)
- Study Status: Open to Enrollment
- Sponsor: Gilead
- Disease Status and/or Stage: Advanced Liver Fibrosis as a Result of NASH (non-lcoholic steatohepatitis)
6.
GS-US-321-0102: GS-6624 in the Prevention of Progression of Liver Fibrosis in Subjects With With Primary Sclerosing Cholangitis (PSC)
- Study Status: Open to Enrollment
- Sponsor: Gilead
- Disease Status and/or Stage: Primary Sclerosing Cholangtis (PSC)
- Protocol ID: GS-US-321-0102
7.
A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer
- Study Status: Open to Enrollment
- Sponsor: Hoffmann-La Roche/Genentech
- Disease Status and/or Stage: Advanced or Metastatic HER2-Positive Gastric or GEJ Cancer
- Protocol ID: BO27952
8.
A Phase Ib Study of Fractionated 90Y-hPAM4 with or without Gemcitabine in Patients with Metastatic Pancreatic Cancer who Received at Least Two Prior Treatments
- Study Status: Closed to Enrollment
- Sponsor: Immunomedics
- Disease Status and/or Stage: Stage IV Metastatic Pancreatic Cancer
- Protocol ID: IM-T-hPAM4-03
9.
An Open-Labeled, Multicenter Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Metastatic Gastric or Gastroesophageal (GEJ) Cancer
10.
A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection (GS-US-283-0102)
- Study Status: Closed to Enrollment
- Sponsor: Gilead
- Disease Status and/or Stage: Chronic Hepatitis B
- Protocol ID: GS-US-283-0102
11.
A Study of Trastuzumab in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
- Study Status: Open to Enrollment
- Sponsor: Genentech/Roche
- Disease Status and/or Stage: Metastatic Gastric Cancer
12.
Study to Evaluate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Combination With Peginterferon α-2a vs Standard of Care Tenofovir Disoproxil Fumarate Monotherapy or Peginterferon α-2a Monotherapy for 48 Weeks in Chronic Hepatitis B
- Study Status: Closed to Enrollment
- Sponsor: Gilead Sciences, Inc.
- Disease Status and/or Stage: Chronic Hepatitis B
13.
REO 022: A Multicenter Phase 1 Study of Intravenous Administration of REOLYSIN® (Reovirus Type 3 Dearing) in Combination with Irinotecan/Fluorouracil/Leucovorin (FOLFIRI) in Patients with Oxaliplatin Refractory/Intolerant KRAS Mutant Colorectal Cancer
- Study Status: Closed to Enrollment
- Sponsor: Oncolytics Biotech, Inc.
- Disease Status and/or Stage: Colon Cancer
14.
Phase I Study of Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy in Patients With Resectable Esophageal Cancer
- Study Status: Closed to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Resectable Cancer of the Esophagus or Gastroesophageal Junction (GEJ)
15.
A random assignment phase II study of modified docetaxel, cisplatin, and fluorouracil (mDCF) versus parent DCF with growth factor support in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma
- Study Status: Open to Enrollment
- Disease Status and/or Stage: Metastatic or Unresectable Gastric or Gastroesophageal Junction (GEJ) Cancer
16.
A Phase 1B, Open-Label, Dose Escalation Study Evaluating the Safety of BSI-201 in Combination with Chemotherapeutic Regimens in Subjects with Advanced Solid Tumors
- Study Status: Closed to Enrollment
- Sponsor: BiPar Sciences
- Disease Status and/or Stage: Metastatic Pancreatic Cancer
17.
A long-term monitoring study to evaluate the persistence of direct acting antiviral (DAA) treatment-resistant mutations or the durability of sustained virological response in patients treated with DAA-containing regimens for chronic hepatitis C infection
- Study Status: Open to Enrollment
- Sponsor: Roche
- Disease Status and/or Stage: Chronic Hepatitis C
